Evidence map›Paper›PMID 39235099›Full record

ArticleCancer medicine2024

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.

Eduardo Terán, Rebeca Lozano, César A Rodríguez, Mar Abad, Luis Figuero, José Antonio Muñoz, Belén Cigarral, Aline Rodrígues, Magdalena Sancho, M Asunción Gómez and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Eduardo TeránMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.ORCID 0000-0001-5643-6506
Rebeca LozanoMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.
César A RodríguezMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.ORCID 0000-0003-3484-4829
Mar AbadInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Luis FigueroMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.
José Antonio MuñozInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Belén CigarralMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.
Aline RodríguesMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.
Magdalena SanchoInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
M Asunción GómezInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Daniel MorchónMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.ORCID 0009-0005-2987-3950
Juan Carlos MonteroInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0003-4773-053X
José María SayaguésInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0003-0582-3500
M Dolores LudeñaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Emilio FonsecaMedical Oncology Department, University Hospital of Salamanca, Salamanca, Spain.

Funding

Roche Diagnostics Costs related to the analysis of samples
6 · The paper itself

Abstract

introductionHotspots (HS) mutations in the PIK3CA gene may lead to poorer oncological outcomes and endocrine resistance in advanced breast cancer (BC), but their prognostic role in early-stage disease remains controversial. The overall agreement within plasma and tissue methods has not been well explored. Our aim was to correlate tissue and plasma approaches and to analyze the prognostic impact of PIK3CA mutations (PIK3CAm) in HR+/HER2- BC.

methodsA retrospective and unicentric analysis of PIK3CA mutational status in tissue and plasma samples by Cobas®PIK3CA Mutation Kit in patients with HR+/HER2- BC.

resultsWe analyzed 225 samples from 161 patients with luminal BC. PIK3CA mutations were identified in 62 patients (38.5%), of which 39.6% were found in tissue and 11.8% in plasma. In advanced disease, plasma and tissue correlation rate was performed in 64 cases, with an overall agreement of 70.3%. Eighty patients were treated with CDK4/6 inhibitors + endocrine therapy. We observed a moderately worse progression-free survival (PFS) in PIK3CAm versus wild-type (WT) (24 m vs. 30 m; HR = 1.39, p = 0.26). A subanalysis was carried out based on exons 9 and 20, which showed a statistically poorer PFS in PIK3CAm exon 9 versus 20 population (9.7 m vs. 30.3 m; HR = 2.84; p = 0.024). Furthermore, detection of PIK3CAm in plasma was linked to a worse PFS vs PIK3CAm detection just in tissue (12.4 vs. 29.3; HR = 2.4; p = 0.08).

conclusionsOur findings suggest the PIK3CA evaluation in tissue as the diagnostic method of choice, however, additional investigations are required to improve the role of liquid biopsy in the PIK3CA assessment. PIK3CAm show worse outcomes in advanced luminal BC, especially in exon 9 mutation carriers, despite visceral involvement, prior exposure to endocrine therapy or detection of PIK3CAm in plasma, with an unclear prognosis in early-stage disease. Nonetheless, this should be validated in a prospective cohort study.

Indexed as

Biomarkers, TumorBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesMutationAdultAgedAged, 80 and overFemaleHumansMiddle AgedPrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPIK3CA protein, humanReceptors, EstrogenReceptors, ProgesteronectDNAcyclin inhibitorsluminal breast cancerPIK3CAtissue

Identifiers

PMID39235099
PMCPMC11375731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.